SEQUENTIAL THERAPY WITH BRENTUXIMAB VEDOTIN IN NEWLY DIAGNOSED PATIENTS WITH SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA

被引：0
|
作者：
Fanale, M. [1 ]
Advani, R. [2 ]
Bartlett, N. L. [3 ]
Davies, A. [4 ]
Illidge, T. [5 ]
Kennedy, D. A. [6 ]
Shustov, A. R. [7 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[3] Washington Univ, Sch Med, St Louis, MO USA
[4] Southampton Univ Hosp, Southampton, Hants, England
[5] Univ Manchester, Christie Hosp NHS, Manchester, Lancs, England
[6] Seattle Genet Inc, Clin Affairs, Bothell, WA USA
[7] Univ Washington, Med Ctr, Div Hematol, Seattle, WA 98195 USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：348 / 348
页数：1
相关论文
共 50 条
  • [1] Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin
    Chen, Xueyan
    Soma, Lorinda A.
    Fromm, Jonathan R.
    ONCOTARGETS AND THERAPY, 2014, 7 : 45 - 56
  • [2] Brentuximab vedotin in anaplastic large cell lymphoma
    Skarbnik, Alan P. Z.
    Smith, Mitchell R.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (05) : 633 - 639
  • [3] Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma
    Vaklavas, Christos
    Forero-Torres, Andres
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (04) : 209 - 225
  • [4] Brentuximab vedotin for previously untreated systemic anaplastic large cell lymphoma
    Calleja, Anne
    Bouclet, Florian
    BULLETIN DU CANCER, 2021, 108 (01) : 12 - 13
  • [5] FDA Approves Brentuximab Vedotin for Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
    不详
    ONCOLOGY-NEW YORK, 2011, 25 (10): : 904 - +
  • [6] Brentuximab vedotin use in pediatric anaplastic large cell lymphoma
    Agrusa, Jennifer E.
    Egress, Emily R.
    Lowe, Eric J.
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [7] Brentuximab Vedotin and Crizotinib in Anaplastic Large-Cell Lymphoma
    Foyil, Kelley V.
    Bartlett, Nancy L.
    CANCER JOURNAL, 2012, 18 (05): : 450 - 456
  • [8] The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Senter, Peter D.
    Sievers, Eric L.
    NATURE BIOTECHNOLOGY, 2012, 30 (07) : 631 - 637
  • [9] Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Illidge, Tim
    Bouabdallah, Reda
    Chen, Robert
    Gopal, Ajay K.
    Moskowitz, Craig H.
    Ramchandren, Radhakrishnan
    Shustov, Andrei R.
    Tilly, Herve
    Trippett, Tanya M.
    Gibb, Adam
    Grove, Laurie E.
    Advani, Ranjana
    LEUKEMIA & LYMPHOMA, 2015, 56 (03) : 703 - 710
  • [10] The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Peter D Senter
    Eric L Sievers
    Nature Biotechnology, 2012, 30 : 631 - 637
12345